Shares of ChemoCentryx Inc. (NASDAQ:CCXI) shot up 6.3% on Tuesday . The company traded as high as $5.42 and last traded at $5.23, with a volume of 158,266 shares. The stock had previously closed at $4.92.

A number of brokerages have recently weighed in on CCXI. Zacks Investment Research cut shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Monday, May 16th. Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a research note on Thursday, May 19th. Finally, JPMorgan Chase & Co. restated a “buy” rating and issued a $11.00 price objective on shares of ChemoCentryx in a research note on Tuesday, August 9th.

The company’s 50-day moving average is $4.60 and its 200-day moving average is $3.87. The company’s market capitalization is $238.81 million.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.